Steglatro FDA Approval History
FDA Approved: Yes (First approved December 19, 2017)
Brand name: Steglatro
Generic name: ertugliflozin
Dosage form: Tablets
Company: Merck
Treatment for: Type 2 Diabetes
Steglatro (ertugliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to help improve glycemic control in adults with type 2 diabetes.
Development timeline for Steglatro
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.